Cahill Financial Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-1,395
Closed -$104K 255
2021
Q3
$104K Buy
+1,395
New +$117K 0.02% 265

Other funds holding ARKG

Cahill Financial Advisors's ARKG Position: Q4 2021 in Review

Cahill Financial Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 1,395 shares — an estimated $104K sold.

Cahill Financial Advisors first reported a position in ARKG in Q3 2021 and held it in 1 quarter. The position peaked at $104K in Q3 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

  • Cahill Financial Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
  • Cahill Financial Advisors sold 1,395 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $104K.
  • Cahill Financial Advisors first reported a position in ARK Genomic Revolution ETF in Q3 2021 and held it in 1 quarter.
  • Cahill Financial Advisors's ARK Genomic Revolution ETF position peaked at $104K in Q3 2021.
  • 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Cahill Financial Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.